| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 15/05/2024 | 13:00 | Business Wire | Harrow to Present at Two Investor Conferences in May | NASDAQ:HROW | Harrow Inc |
| 13/05/2024 | 22:01 | Business Wire | Harrow Announces First Quarter 2024 Financial Results | NASDAQ:HROW | Harrow Inc |
| 13/05/2024 | 13:00 | Business Wire | Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial | NASDAQ:HROW | Harrow Inc |
| 25/04/2024 | 13:00 | Business Wire | Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 | NASDAQ:HROW | Harrow Inc |
| 02/04/2024 | 14:16 | Business Wire | Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing | NASDAQ:HROW | Harrow Inc |
| 20/03/2024 | 12:15 | IH Market News | JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News | NASDAQ:HROW | Harrow Inc |
| 19/03/2024 | 22:45 | Business Wire | Harrow Announces Fourth Quarter and Year-End 2023 Financial Results | NASDAQ:HROW | Harrow Inc |
| 19/03/2024 | 12:27 | IH Market News | US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat | NASDAQ:HROW | Harrow Inc |
| 06/03/2024 | 12:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:HROW | Harrow Inc |
| 05/03/2024 | 13:00 | Business Wire | Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 | NASDAQ:HROW | Harrow Inc |
| 15/02/2024 | 22:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:HROW | Harrow Inc |
| 15/02/2024 | 22:01 | Business Wire | Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products | NASDAQ:HROW | Harrow Inc |
| 09/02/2024 | 22:05 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:HROW | Harrow Inc |
| 29/01/2024 | 21:26 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:HROW | Harrow Inc |
| 29/01/2024 | 13:00 | Business Wire | Harrow Announces New Appointments to its Board of Directors | NASDAQ:HROW | Harrow Inc |
| 11/01/2024 | 13:00 | Business Wire | Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease | NASDAQ:HROW | Harrow Inc |
| 03/01/2024 | 13:15 | Business Wire | Melt Pharmaceuticals Provides Corporate Update | NASDAQ:HROW | Harrow Inc |
| 03/01/2024 | 13:00 | Business Wire | Harrow Partners with Leading Healthcare Market Access Technology Platforms | NASDAQ:HROW | Harrow Inc |
| 29/11/2023 | 13:00 | Business Wire | Harrow Completes Transfer of the TRIESENCE® New Drug Application | NASDAQ:HROW | Harrow Inc |
| 20/11/2023 | 13:00 | Business Wire | Harrow to Present at Two Investor Conferences in November | NASDAQ:HROW | Harrow Inc |
| 13/11/2023 | 22:38 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:HROW | Harrow Inc |
| 13/11/2023 | 22:01 | Business Wire | Harrow Announces Third Quarter 2023 Financial Results | NASDAQ:HROW | Harrow Inc |
| 30/10/2023 | 13:00 | Business Wire | Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 | NASDAQ:HROW | Harrow Inc |
| 24/10/2023 | 13:00 | Business Wire | Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S. | NASDAQ:HROW | Harrow Inc |
| 29/09/2023 | 14:00 | Business Wire | Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. | NASDAQ:HROW | Harrow Inc |
| 26/09/2023 | 14:00 | Business Wire | Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation | NASDAQ:HROW | Harrow Inc |
| 09/08/2023 | 22:01 | Business Wire | Harrow Announces Second Quarter 2023 Financial Results | NASDAQ:HROW | Harrow Inc |
| 31/07/2023 | 13:00 | Business Wire | Harrow Launches VIGAMOX® in the U.S. | NASDAQ:HROW | Harrow Inc |
| 26/07/2023 | 15:00 | Business Wire | Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 | NASDAQ:HROW | Harrow Inc |
| 19/07/2023 | 23:19 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:HROW | Harrow Inc |